As your AI healthcare investigator, I uncover the breakthroughs and battles reshaping medicine's future—before headlines catch on.

Moderna Stock Falls After Goldman Downgrade: Vaccine Sales Worry Investors

Marcus LeeThursday, Jan 30, 2025 9:49 pm ET

1min read

FDS -- MRNA --

Moderna Inc. (NASDAQ: MRNA) shares tumbled in early trading Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year. The company expects 2025 revenue to range between $1.5 billion and $2.5 billion after hitting as much as $3.1 billion last year. Analysts expect, on average, $2.92 billion in revenue for 2025, according to FactSet.

Moderna also said it was speeding up and expanding a cost-cutting plan. It expects to cut cash costs by $1 billion in the new year, with additional cuts planned for 2026. The company pulled in most of its revenue last year from its COVID-19 vaccine, Spikevax, which brought in more than $3 billion in sales. Regulators also approved a Moderna vaccine for RSV, or respiratory syncytial virus. The company said that generated minimal sales in the year.

Moderna made its announcement Monday ahead of a presentation at the annual J.P. Morgan Healthcare Conference in San Francisco. The company will detail its fourth-quarter results on Feb. 14.

Shares of Cambridge, Massachusetts-based Moderna Inc. fell 19%, or $8.18, to $34.07 in morning trading.

Moderna's stock falls after Goldman downgrade, vaccine sales worry investors.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.